MA29984B1 - Antagonistes du recepteur de crf et procedes correspondants - Google Patents

Antagonistes du recepteur de crf et procedes correspondants

Info

Publication number
MA29984B1
MA29984B1 MA29147A MA29147A MA29984B1 MA 29984 B1 MA29984 B1 MA 29984B1 MA 29147 A MA29147 A MA 29147A MA 29147 A MA29147 A MA 29147A MA 29984 B1 MA29984 B1 MA 29984B1
Authority
MA
Morocco
Prior art keywords
crf receptor
receptor antagonists
methods
crf
pharmaceutically acceptable
Prior art date
Application number
MA29147A
Other languages
English (en)
Inventor
Zhiyong Luo
Deborah Slee
John Edward Tellew
John Williams
Xiaohu Zhang
Original Assignee
Neurocrine Biosciences Inc
Sb Pharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc, Sb Pharmco Inc filed Critical Neurocrine Biosciences Inc
Publication of MA29984B1 publication Critical patent/MA29984B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Antagonistes du récepteur de CRF et méthodes les concernant Il est décrit des antagonistes du récepteur de CRF qui sont utiles dans le traitement de diverses affections, comprenant le traitement d'affections se manifestant par une hypersécrétion de CRF chez des animaux à sang chaud, telles qu'un ictus. Les antagonistes du récepteur de CRF de la présente invention ont la structure (I) suivante, et comprennent leurs stéréoisomères, leurs précurseurs médicamenteux et leurs sels pharmaceutiquement acceptables, structure dans laquelle R1, R2, R3, Y, Ar et H et sont tels que définis dans le présent mémoire. Il est décrit également des compositions contenant un antagoniste du récepteur de CRF en association avec un support pharmaceutiquement acceptable, ainsi que des méthodes pour leur utilisation.
MA29147A 2003-12-22 2006-06-27 Antagonistes du recepteur de crf et procedes correspondants MA29984B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53203103P 2003-12-22 2003-12-22

Publications (1)

Publication Number Publication Date
MA29984B1 true MA29984B1 (fr) 2008-12-01

Family

ID=34738733

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29147A MA29984B1 (fr) 2003-12-22 2006-06-27 Antagonistes du recepteur de crf et procedes correspondants

Country Status (19)

Country Link
US (1) US7737154B2 (fr)
EP (1) EP1697374B1 (fr)
JP (1) JP4926720B2 (fr)
KR (1) KR20070009537A (fr)
CN (1) CN1938309B (fr)
AR (1) AR046967A1 (fr)
AU (1) AU2004309168B2 (fr)
BR (1) BRPI0417943A (fr)
CA (1) CA2550948A1 (fr)
IL (1) IL176350A0 (fr)
IS (1) IS8526A (fr)
MA (1) MA29984B1 (fr)
MY (1) MY143499A (fr)
NO (1) NO20063230L (fr)
NZ (1) NZ547990A (fr)
RU (1) RU2394035C2 (fr)
TW (1) TW200530242A (fr)
WO (1) WO2005063755A1 (fr)
ZA (1) ZA200604574B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US7652035B2 (en) * 2004-10-19 2010-01-26 Neurocrine Bioscience, Inc. CRF receptor antagonists and methods relating thereto
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
KR101088239B1 (ko) 2006-09-20 2011-11-30 일라이 릴리 앤드 캄파니 Ｃｒｆ１ 수용체 길항제로서의 티아졸 피라졸로피리미딘
MX2009003098A (es) 2006-09-20 2009-04-01 Lilly Co Eli Compuestos de tiofen pirazolopirimidina.
KR100854679B1 (ko) * 2007-02-03 2008-08-27 김기형 심플 서비스 로케이션 프로토콜 네트워크 시스템 및 이를구성하는 에이전트.
EP2282998B1 (fr) * 2008-04-21 2014-09-10 Albemarle Corporation Procédés de production du n-alkylpyrazole
EP2531490B1 (fr) * 2010-02-02 2014-10-15 Novartis AG Dérivés de cyclohexylamide à titre d'antagonistes du récepteur crf
WO2014060381A1 (fr) 2012-10-18 2014-04-24 Bayer Cropscience Ag Composés hétérocycliques pour la lutte contre les nuisibles
US20150284380A1 (en) 2012-10-31 2015-10-08 Bayer Cropscience Ag Novel heterocyclic compounds as pest control agents
JP6359175B2 (ja) * 2014-04-10 2018-07-18 フーベイ バイオ−ファーマシューティカル インダストリアル テクノロジカル インスティテュート インコーポレイテッド ＰＡＲＰ阻害剤としての４Ｈ‐ピラゾロ［１，５‐α］ベンゾイミダゾール化合物のアナログ
BR112020002967A2 (pt) 2017-08-14 2020-08-11 Spruce Biosciences, Inc. antagonistas de receptor de fator de liberação de corticotropina
MX2020011344A (es) 2018-04-27 2021-02-09 Spruce Biosciences Inc Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
CA3187362A1 (fr) 2020-07-27 2022-02-03 John Thomas Feutrill Composes
JP2023537598A (ja) 2020-08-12 2023-09-04 スプルース バイオサイエンシーズ，インク． 多嚢胞性卵巣症候群を処置するための方法および組成物
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2168237T3 (es) * 1996-02-07 2007-04-01 Neurocrine Biosciences, Inc. Pirazolopirimidinas como antagonistas de receptores de crf.
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
AU747708B2 (en) 1996-07-24 2002-05-23 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
PL332040A1 (en) 1996-08-28 1999-08-16 Pfizer Substitution 6,5-heterobicyclic derivatives
CA2291709A1 (fr) * 1997-05-30 1998-12-03 Merck & Co., Inc. Nouveaux inhibiteurs d'angiogenese
IL137019A0 (en) * 1998-01-28 2001-06-14 Du Pont Pharm Co Azolo triazines and pyrimidines
AU4203500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
YU23602A (sh) * 1999-09-30 2004-09-03 Neurogen Corporation Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini
IL139197A0 (en) * 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
CA2446514A1 (fr) * 2001-04-30 2002-11-07 Glaxo Group Limited Pyrimidines fondues utilisees en tant qu'antagonistes de la corticoliberine (crf)
ATE397609T1 (de) * 2001-06-12 2008-06-15 Glaxo Group Ltd Corticotropinfreisetzungsfaktor antagonisten
GB0117396D0 (en) * 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
EP1583531B1 (fr) * 2003-01-16 2007-04-18 SB Pharmco Puerto Rico Inc Derives pyrrolo[2,3- b]pyridine a substitution heteroaryle utilises comme antagonistes des recepteurs du crf
WO2004087707A1 (fr) 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Composes pyrazolopyrimidines et leur utilisation en medecine
US20070021429A1 (en) * 2003-04-09 2007-01-25 Yves St-Denis Condensed n-heterocyclic compounds and their use as crf receptor antagonists
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US20070293511A1 (en) * 2003-12-22 2007-12-20 Sb Pharmco Puerto Rico Inc. And Neurocrine Biosciences, Inc., A Corporation Crf Receptor Antagonists and Methods
DE102004008807A1 (de) * 2004-02-20 2005-09-08 Bayer Cropscience Ag Pyrazolopyrimidine
US7652035B2 (en) * 2004-10-19 2010-01-26 Neurocrine Bioscience, Inc. CRF receptor antagonists and methods relating thereto
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists

Also Published As

Publication number Publication date
EP1697374B1 (fr) 2012-08-29
AR046967A1 (es) 2006-01-04
CA2550948A1 (fr) 2005-07-14
RU2006126675A (ru) 2008-01-27
NZ547990A (en) 2010-04-30
AU2004309168A1 (en) 2005-07-14
US20070287705A1 (en) 2007-12-13
CN1938309B (zh) 2011-11-09
NO20063230L (no) 2006-09-12
BRPI0417943A (pt) 2007-04-17
RU2394035C2 (ru) 2010-07-10
MY143499A (en) 2011-05-31
WO2005063755A1 (fr) 2005-07-14
IS8526A (is) 2006-07-11
AU2004309168B2 (en) 2009-04-23
TW200530242A (en) 2005-09-16
ZA200604574B (en) 2007-11-28
JP4926720B2 (ja) 2012-05-09
JP2007515472A (ja) 2007-06-14
EP1697374A1 (fr) 2006-09-06
KR20070009537A (ko) 2007-01-18
US7737154B2 (en) 2010-06-15
CN1938309A (zh) 2007-03-28
IL176350A0 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
TNSN05249A1 (fr) Benzopyrannes utiles pour le traitement d'etats inflammatoires
TNSN06358A1 (fr) Methyl-aryl-ou-heteroaryl-amides substitues
MA31763B1 (fr) Inhibiteurs de kinase de type polo
TNSN06359A1 (fr) Aryl-ou heteroaryl-amides substitues en position ortho
TNSN06347A1 (fr) Derives de morpholine
MA27142A1 (fr) Derives de piperazine a activite antagoniste des recepteurs ccr1
TNSN07349A1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
TNSN05250A1 (fr) Pyrimidinones substituees
MA27582A1 (fr) Derives benzazepine pour le traitement de troubles neurologiques
TNSN06109A1 (fr) Derives [3.1.0] bicycliques servant d'inhibiteurs du transporteur de glycine
DE60305484D1 (de) Verbindungen und deren verwendung als 5-ht inhibitore
MA29713B1 (fr) Derives de tetrahydroindolone et de tetrahydroindazolone
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA30075B1 (fr) Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
MA29250B1 (fr) Cyclohexylamides servant d'antagonistes des recepteurs de dopamine d3, d2 et de 5ht1a
MA31373B1 (fr) Composes amino-heterocycliques
MA27568A1 (fr) Derives de pyrrolopyrimidine
MA27569A1 (fr) Derives de pyrrolo-pyrazole substitues servant d'inhibiteurs de kinases
TN2009000204A1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase
MA29672B1 (fr) [3.1.0] hétéroarylamides bicycliques servant d'inhibiteurs du transport de glycine de type I
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA27197A1 (fr) Sels de tolterodine
MA30756B1 (fr) Derives de cinnamoyl-piperazine et leur utilisation comme antagonistes par-1
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
MA50069B1 (fr) Dérivés 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-méthylpropan-2-ol et composés similaires en tant qu'inhibiterus il-7 et ifn-gamma pour le traitement de maladies autoimmune et inflammation chronique